Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.

Advances in the treatment of heart failure may require manipulation of neurohumoral responses to cardiac impairment in addition to the established strategy of angiotensin-converting enzyme (ACE) inhibition. Importantly, since new treatments are likely to be used in conjunction with ACE inhibition therapy, the effects of the combination of agents need to be assessed. Adrenomedullin (ADM) is a peptide with potent vasodilator and natriuretic actions. ADM and an ACE inhibitor (captopril) were administered for 3 h both separately and together in eight sheep with heart failure. Both ADM and captopril alone reduced arterial pressure, left atrial pressure (greater with captopril) and peripheral resistance, and increased cardiac output (greater with ADM). Compared with either treatment separately, combined ADM+captopril produced directionally similar but significantly greater changes in all haemodynamic variables (particularly falls in blood pressure). ADM increased renal sodium and creatinine excretion and creatinine clearance, and maintained urine output. Captopril and ADM+captopril reduced creatinine excretion and creatinine clearance, while urine volume and sodium excretion were not significantly altered. Plasma renin activity rose with all active treatments, whereas angiotensin II levels rose during ADM, but fell during captopril and ADM+captopril. Aldosterone was reduced by all active treatments. ADM+captopril reduced plasma noradrenaline (norepinephrine). In conclusion, short-term co-treatment with ADM and an ACE inhibitor produced significantly greater decreases in ventricular filling pressures and cardiac afterload, and increases in cardiac output, compared with either treatment alone. Despite the greater falls in blood pressure (and presumably renal perfusion pressure), renal function was maintained at a level similar to that observed with captopril alone.

[1]  S Capewell,et al.  More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.

[2]  R. Doughty,et al.  Clinical use of beta-blocker therapy in patients with heart failure: a practical guide. , 2001, The New Zealand medical journal.

[3]  N. Sharpe Heart failure management: 25 years of progress. , 2001, The New Zealand medical journal.

[4]  K. Kangawa,et al.  Comparison of intravenous adrenomedullin with atrial natriuretic peptide in patients with congestive heart failure. , 2000, The American journal of cardiology.

[5]  K. Kangawa,et al.  Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. , 2000, Circulation.

[6]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 1999, Journal of the American College of Cardiology.

[7]  N. Toda,et al.  Inhibition by adrenomedullin of amine release from adrenergic nerves in dog mesenteric arteries. , 1999, European journal of pharmacology.

[8]  M. Kähönen,et al.  Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. , 1999, Journal of hypertension.

[9]  D. Martineau,et al.  Functional role of local angiotensin-converting enzyme (ACE) in adrenal catecholamine secretion in vivo. , 1999, Canadian journal of physiology and pharmacology.

[10]  A. Richards,et al.  Bioactivity and interactions of adrenomedullin and brain natriuretic peptide in patients with heart failure. , 1999, Hypertension.

[11]  J. Burnett,et al.  Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. , 1998, American journal of physiology. Renal physiology.

[12]  A. Richards,et al.  Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. , 1998, Clinical chemistry.

[13]  A. Richards,et al.  Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. , 1998, Journal of cardiovascular pharmacology.

[14]  J. Cockcroft,et al.  Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels. , 2003, British journal of clinical pharmacology.

[15]  M. Nicholls,et al.  Degradation of Human Adrenomedullin(1-52) by Plasma Membrane Enzymes and Identification of Metabolites , 1997, Peptides.

[16]  G. Cooper,et al.  Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. , 1997, Circulation.

[17]  G. Cooper,et al.  Hemodynamic, hormonal, and renal effects of adrenomedullin in conscious sheep. , 1997, The American journal of physiology.

[18]  B. Krämer,et al.  Adrenomedullin stimulates renin release and renin mRNA in mouse juxtaglomerular granular cells. , 1997, Hypertension.

[19]  L. Malendowicz,et al.  Effects of adrenomedullin on the human adrenal glands: an in vitro study. , 1997, The Journal of clinical endocrinology and metabolism.

[20]  K. Chatterjee Inhibitors of the renin-angiotensin system in established cardiac failure , 1996, Heart.

[21]  T. Horio,et al.  Interaction of adrenomedullin and platelet-derived growth factor on rat mesangial cell production of endothelin. , 1996, Hypertension.

[22]  H. Ruskoaho,et al.  Inotropic effect of adrenomedullin in the isolated perfused rat heart. , 1996, Acta physiologica Scandinavica.

[23]  T. Ishimitsu,et al.  Increased plasma levels of adrenomedullin in patients with heart failure. , 1995, Journal of the American College of Cardiology.

[24]  M. Fujishima,et al.  Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. , 1995, The American journal of physiology.

[25]  H. Lippton,et al.  Vasodilator effect of human adrenomedullin(13-52) on hypertensive rats. , 1995, Canadian journal of physiology and pharmacology.

[26]  D. Parkes Cardiovascular actions of adrenomedullin in conscious sheep. , 1995, The American journal of physiology.

[27]  O. Kohmoto,et al.  Mechanisms of adrenomedullin-induced vasodilation in the rat kidney. , 1995, Hypertension.

[28]  N. Minamino,et al.  Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells. , 1994, Biochemical and biophysical research communications.

[29]  C. Lang,et al.  Effect of angiotensin-converting enzyme inhibition on plasma brain natriuretic peptide levels in patients with heart failure. , 1992, Clinical science.

[30]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[31]  C. Frampton,et al.  Hemodynamic and hormonal effects of renin inhibition in ovine heart failure. , 1990, The American journal of physiology.

[32]  E. Espiner,et al.  Neurohumoral changes during onset and offset of ovine heart failure: role of ANP. , 1989, The American journal of physiology.

[33]  R. Dietz,et al.  Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems. , 1987, The American journal of cardiology.

[34]  J. Cohn,et al.  Effect of captopril on renal function in patients with congestive heart failure. , 1981, British heart journal.

[35]  J. O. Davis,et al.  Mechanisms regulating renin release. , 1976, Physiological reviews.